Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.53
AVEO's Cash to Debt is ranked higher than
61% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. AVEO: 2.53 )
AVEO' s 10-Year Cash to Debt Range
Min: 1.54   Max: 9.15
Current: 2.53

1.54
9.15
Equity to Asset 0.29
AVEO's Equity to Asset is ranked higher than
53% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AVEO: 0.29 )
AVEO' s 10-Year Equity to Asset Range
Min: -3.21   Max: 0.76
Current: 0.29

-3.21
0.76
F-Score: 2
Z-Score: -10.16
M-Score: 7.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -278.35
AVEO's Operating margin (%) is ranked higher than
64% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. AVEO: -278.35 )
AVEO' s 10-Year Operating margin (%) Range
Min: -8035.89   Max: 20.59
Current: -278.35

-8035.89
20.59
Net-margin (%) -290.99
AVEO's Net-margin (%) is ranked higher than
63% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. AVEO: -290.99 )
AVEO' s 10-Year Net-margin (%) Range
Min: -8277.57   Max: 18.59
Current: -290.99

-8277.57
18.59
ROE (%) -111.72
AVEO's ROE (%) is ranked higher than
55% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. AVEO: -111.72 )
AVEO' s 10-Year ROE (%) Range
Min: -116.49   Max: 20.76
Current: -111.72

-116.49
20.76
ROA (%) -49.26
AVEO's ROA (%) is ranked higher than
61% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. AVEO: -49.26 )
AVEO' s 10-Year ROA (%) Range
Min: -88.25   Max: 13.74
Current: -49.26

-88.25
13.74
ROC (Joel Greenblatt) (%) -336.35
AVEO's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. AVEO: -336.35 )
AVEO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1669.78   Max: 678.74
Current: -336.35

-1669.78
678.74
Revenue Growth (3Y)(%) -55.50
AVEO's Revenue Growth (3Y)(%) is ranked higher than
57% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. AVEO: -55.50 )
AVEO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -25.2
Current: -55.5

» AVEO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AVEO Guru Trades in Q1 2014

Steven Cohen 500,000 sh (New)
Seth Klarman 3,829,350 sh (unchged)
Chuck Royce Sold Out
Jim Simons 1,275,453 sh (-1.82%)
Paul Tudor Jones 106,701 sh (-2.20%)
» More
Q2 2014

AVEO Guru Trades in Q2 2014

George Soros 49,076 sh (New)
Jim Simons 1,343,488 sh (+5.33%)
Paul Tudor Jones 106,701 sh (unchged)
Seth Klarman 3,829,350 sh (unchged)
» More
Q3 2014

AVEO Guru Trades in Q3 2014

Seth Klarman 3,829,350 sh (unchged)
George Soros Sold Out
Paul Tudor Jones 99,319 sh (-6.92%)
Jim Simons 591,700 sh (-55.96%)
» More
Q4 2014

AVEO Guru Trades in Q4 2014

Jim Simons 675,800 sh (+14.21%)
Seth Klarman Sold Out
Seth Klarman Sold Out
Paul Tudor Jones 88,219 sh (-11.18%)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.80
AVEO's P/B is ranked higher than
71% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. AVEO: 4.80 )
AVEO' s 10-Year P/B Range
Min: 0.87   Max: 22.16
Current: 4.8

0.87
22.16
P/S 5.54
AVEO's P/S is ranked higher than
83% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. AVEO: 5.54 )
AVEO' s 10-Year P/S Range
Min: 1.06   Max: 111.5
Current: 5.54

1.06
111.5
Current Ratio 1.47
AVEO's Current Ratio is ranked higher than
54% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. AVEO: 1.47 )
AVEO' s 10-Year Current Ratio Range
Min: 1.47   Max: 6.77
Current: 1.47

1.47
6.77
Quick Ratio 1.47
AVEO's Quick Ratio is ranked higher than
57% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. AVEO: 1.47 )
AVEO' s 10-Year Quick Ratio Range
Min: 1.47   Max: 6.77
Current: 1.47

1.47
6.77
Days Sales Outstanding 47.15
AVEO's Days Sales Outstanding is ranked higher than
87% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. AVEO: 47.15 )
AVEO' s 10-Year Days Sales Outstanding Range
Min: 3.19   Max: 390.8
Current: 47.15

3.19
390.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 48.00
AVEO's Price/Net Cash is ranked higher than
58% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. AVEO: 48.00 )
AVEO' s 10-Year Price/Net Cash Range
Min: 2.26   Max: 21
Current: 48

2.26
21
Price/Net Current Asset Value 24.00
AVEO's Price/Net Current Asset Value is ranked higher than
62% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. AVEO: 24.00 )
AVEO' s 10-Year Price/Net Current Asset Value Range
Min: 1.81   Max: 7.86
Current: 24

1.81
7.86
Price/Tangible Book 4.90
AVEO's Price/Tangible Book is ranked higher than
76% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. AVEO: 4.90 )
AVEO' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 14.66
Current: 4.9

1.2
14.66
Price/Median PS Value 1.10
AVEO's Price/Median PS Value is ranked higher than
83% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. AVEO: 1.10 )
AVEO' s 10-Year Price/Median PS Value Range
Min: 0.56   Max: 10.76
Current: 1.1

0.56
10.76
Earnings Yield (Greenblatt) -80.00
AVEO's Earnings Yield (Greenblatt) is ranked lower than
70% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. AVEO: -80.00 )
AVEO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -80   Max: 48134.7
Current: -80

-80
48134.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:VPA.Germany,
AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The Company's proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company unique insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
comment on AVEO Mar 15 2013 
comment on AVEO Mar 15 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Our Partners
Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog Apr 17 2015 - ZACKS

More From Other Websites
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog Apr 24 2015
Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog Apr 23 2015
Acorda Reports Encouraging Data on MS Drug - Analyst Blog Apr 23 2015
Emergent BioSolutions Resumes BioThrax Manufacturing - Analyst Blog Apr 23 2015
Capricor's CAP-1002 Gets Orphan Drug Status in the U.S. - Analyst Blog Apr 23 2015
Eli Lilly Beats on 1Q Earnings by Wide Margin, Affirms View - Analyst Blog Apr 23 2015
Alexion Misses Q1 Earnings Estimates, Keeps 2015 Outlook - Analyst Blog Apr 23 2015
Zacks Rank #1 Additions for Thursday - Tale of the Tape Apr 23 2015
Four one-time biotech underdogs are outperforming the market this year Apr 22 2015
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 22 2015
AVEO Names Keith S. Ehrlich as Chief Financial Officer Apr 22 2015
AVEO Names Keith S. Ehrlich as Chief Financial Officer Apr 22 2015
The Medicines Co.'s New Minocin Formulation Approved - Analyst Blog Apr 21 2015
Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog Apr 21 2015
AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue? - Tale of the Tape Apr 21 2015
Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog Apr 20 2015
Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog Apr 20 2015
TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog Apr 20 2015
Zacks Rank #1 Additions for Monday - Tale of the Tape Apr 20 2015
AVEO Oncology Announces Presentation of AV-380 Preclinical Data in Cancer Associated Cachexia at... Apr 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK